Smith & Nephew plc (SNN)
- Previous Close
23.88 - Open
24.53 - Bid 23.83 x 1100
- Ask 24.87 x 900
- Day's Range
24.33 - 24.61 - 52 Week Range
21.53 - 32.81 - Volume
1,759,851 - Avg. Volume
959,409 - Market Cap (intraday)
10.689B - Beta (5Y Monthly) 0.51
- PE Ratio (TTM)
40.75 - EPS (TTM)
0.60 - Earnings Date --
- Forward Dividend & Yield 0.75 (3.07%)
- Ex-Dividend Date Apr 1, 2024
- 1y Target Est
31.50
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
www.smith-nephew.comRecent News: SNN
Performance Overview: SNN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNN
Valuation Measures
Market Cap
10.73B
Enterprise Value
13.51B
Trailing P/E
40.61
Forward P/E
12.42
PEG Ratio (5yr expected)
0.46
Price/Sales (ttm)
1.92
Price/Book (mrq)
2.05
Enterprise Value/Revenue
2.43
Enterprise Value/EBITDA
14.13
Financial Highlights
Profitability and Income Statement
Profit Margin
4.74%
Return on Assets (ttm)
4.27%
Return on Equity (ttm)
5.02%
Revenue (ttm)
5.55B
Net Income Avi to Common (ttm)
263M
Diluted EPS (ttm)
0.60
Balance Sheet and Cash Flow
Total Cash (mrq)
302M
Total Debt/Equity (mrq)
59.11%
Levered Free Cash Flow (ttm)
211.75M
Research Analysis: SNN
Company Insights: SNN
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: SNN
Analyst Report: Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
RatingPrice TargetAnalyst Report: Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
RatingPrice TargetAnalyst Report: Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
RatingPrice TargetAnalyst Report: Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
RatingPrice Target